Narrowband-UVB treatments effect on S100A8/A9 protein and gene expression in psoriasis skin and serum in individuals with plaque psoriasis.

Narrowband-UVB treatments effect on S100A8/A9 protein and gene expression in psoriasis skin and serum in individuals with plaque psoriasis. - PSOKAL

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00014817

Enrollment

Registered

2018-06-11

Start date

2013-12-09

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

L40

Interventions

Group 1: S100A8/A9 gene expression and protein expression levels in lesional, non-lesional skin and blood are studied in Swedish plaque psoriasis patients receiving narrowband UVB treatment (20-25 tre

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Plaque psoriasis

Exclusion criteria

Exclusion criteria: Pregnancy Other chronic inflammatory disease Psoriasis Arthritis (Active) Ongoing infection Systemic psoriasis treatment Recent high UV exposure Unability to give informed consent to study

Design outcomes

Primary

Measure	Time frame
Gene and protein expression of S100A8/A9 in response to disease improvement measured with psoriasis area severity index (PASI). Skin levels (biopsies) are performed before and after a complete NB-UVB treatment (20-25 sessions). Serum samples are taken after every 5 NB-UVB sessions.	—

Secondary

Measure	Time frame
Is serum S100A8/A9 a potential Clinical biomarker for psoriasis disease activity?	—

Countries

Sweden

Contacts

Public ContactAlbert Duvetorp

IKE Linköpings Universitet, Skåne University Hospital Malmö

albert.duvetorp@skane.se+46736166946

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026